Unicycive Therapeutics resubmits FDA new drug application for oxylanthanum carbonate

Unicycive Therapeutics resubmitted its FDA New Drug Application for oxylanthanum carbonate, a treatment for hyperphosphatemia in chronic kidney disease patients on dialysis. The company expects a PDUFA date six months from the resubmission date.

Detected & updated continuously · Source: Nebula